Ju Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ju Liu has a total of 571 co-authors. Here are the top co-authors by number of shared publications:
Fengyun Dong
Laboratory of Microvascular Medicine, Medical Research Center, Shandong Provincial Qianfoshan Hospital, The First Affiliated Hospital of Shandong First Medical University, 16766 Jingshi Road, Jinan, Shandong 250014, China
22 shared publicationsLiqun Li
Department of Clinical Laboratory, Qingdao Municipal Hospital, University of Health and Rehabilitation Sciences, Qingdao, Shandong, China
21 shared publicationsJing Liu
Laboratory of Translational Medicine in Microvascular Regulation, Medical Research Center, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, Shandong 250014, P.R. China
16 shared publicationsQiang Liu
Laboratory of Translational Medicine in Microvascular Regulation, Medical Research Center,The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital; Shandong Provincial Key Laboratory of Medicine in Microvascular Ageing; Laboratory of Future Industry of Gene Editing in Vascular Endothelial Cells of Universities in Shandong Province Jinan China
16 shared publications- Thaddeus D. Allen
J. Michael Bishop Institute of Cancer Research
13 shared publications Fuhong Liu
12 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by Spandidos Publications in Biomedical Reports
- Vol. 26 (1) , 1-9
Soluble CD109 released from lung adenocarcinoma cells activates the STAT3 signaling pathway to promote lymphatic endothelial cell migration
Lung adenocarcinoma (LUAD), the predominant subtype of non‑small cell lung cancer, frequently metastasizes to regional lymph nodes through the lymphatic system. CD109 is upregulated in LUAD and is associated with poor prognosis; however, its effects on lymphatic endothelial cells remain poorly characterized. The present study investigated whether soluble CD109 released from LUAD cells influences lymphatic endothelial cell function and explored the underlying molecular mechanisms. CD109 was overexpressed in human LUAD A549 cells using an adenoviral vector. Conditioned medium (CD109‑CM) was collected following demonstration of CD109 expression and secretion using reverse transcription‑quantitative PCR and western blotting. The effects of soluble CD109 on human dermal lymphatic endothelial cells (HDLECs) were evaluated using proliferation and migration assays. Involvement of the Janus kinase 2 (JAK2)/STAT3 signaling pathway was examined using western blotting and further evaluated using Stattic, a STAT3 inhibitor. CD109 overexpression in A549 cells significantly increased both cellular and secreted CD109 levels. Despite CD109‑CM having not significantly affected HDLEC proliferation, it markedly enhanced HDLEC migration. Mechanistically, CD109‑CM increased JAK2 and STAT3 phosphorylation in HDLECs, consistent with activation of STAT3 signaling. Pharmacological inhibition of STAT3 signaling with Stattic attenuated STAT3 phosphorylation and abolished the CD109‑CM‑induced increase in HDLEC migration. Collectively, these findings demonstrated that soluble CD109 released from LUAD cells may promote lymphatic endothelial cell migration through activation of JAK2/STAT3 signaling. The present in vitro findings identified the CD109‑JAK2/STAT3 axis as a potential mechanism through which LUAD cells modulate lymphatic endothelial cell behavior, thus supporting further in vivo investigation of CD109 as a potential therapeutic target in LUAD.
- 9 November 2026
- Published by Spandidos Publications in Biomedical Reports
- Vol. 26 (1) , 1-9
Open AccessSoluble CD109 released from lung adenocarcinoma cells activates the STAT3 signaling pathway to promote lymphatic endothelial cell migration
Lung adenocarcinoma (LUAD), the predominant subtype of non‑small cell lung cancer, frequently metastasizes to regional lymph nodes through the lymphatic system. CD109 is upregulated in LUAD and is associated with poor prognosis; however, its effects on lymphatic endothelial cells remain poorly characterized. The present study investigated whether soluble CD109 released from LUAD cells influences lymphatic endothelial cell function and explored the underlying molecular mechanisms. CD109 was overexpressed in human LUAD A549 cells using an adenoviral vector. Conditioned medium (CD109‑CM) was collected following demonstration of CD109 expression and secretion using reverse transcription‑quantitative PCR and western blotting. The effects of soluble CD109 on human dermal lymphatic endothelial cells (HDLECs) were evaluated using proliferation and migration assays. Involvement of the Janus kinase 2 (JAK2)/STAT3 signaling pathway was examined using western blotting and further evaluated using Stattic, a STAT3 inhibitor. CD109 overexpression in A549 cells significantly increased both cellular and secreted CD109 levels. Despite CD109‑CM having not significantly affected HDLEC proliferation, it markedly enhanced HDLEC migration. Mechanistically, CD109‑CM increased JAK2 and STAT3 phosphorylation in HDLECs, consistent with activation of STAT3 signaling. Pharmacological inhibition of STAT3 signaling with Stattic attenuated STAT3 phosphorylation and abolished the CD109‑CM‑induced increase in HDLEC migration. Collectively, these findings demonstrated that soluble CD109 released from LUAD cells may promote lymphatic endothelial cell migration through activation of JAK2/STAT3 signaling. The present in vitro findings identified the CD109‑JAK2/STAT3 axis as a potential mechanism through which LUAD cells modulate lymphatic endothelial cell behavior, thus supporting further in vivo investigation of CD109 as a potential therapeutic target in LUAD.
- Open Access
- 2 November 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1764090
Ginsenoside Rg1 reduces endothelial cell injury in transplant-associated thromboticmicroangiopathy by regulating the expression of HIF-1α
Purpose: Transplant-Associated Thromboticmicroangiopathy (TA-TMA) is a common complication after hematopoietic stem cell transplantation (HSCT) with poor prognosis. This study aimed to explore the role and the regulation of Hypoxia-inducible factor-1α (HIF-1α) in TA-TMA. In addition, the effect of Ginsenoside Rg1 on TA-TMA endothelial cells was also explored. Method: We constructed a TA-TMA endothelial cell model using plasma from TA-TMA patients. A TA-TMA mouse model was successfully constructed by upregulating the expression of HIF-1α using Dimethyloxallyl Glycine(DMOG) in the HSCT mice. AKT inhibitor MK2206 and STAT3 inhibitor stattic were applied to TA-TMA endothelial cells, and the expression of AKT/STAT3/HIF-1α axis was detected. Endothelial cells were divided into control group, TA-TMA group and TA-TMA+Rg1 group. The proliferation, apoptosis and related proteins expression of endothelial cells were detected. Results: A-TMA plasma leaded to the toxicity of endothelial cells. The expression of p-AKT, p-STAT3, and HIF-1α/Plasminogen Activator Inhibitor-1 (PAI-1) was significantly increased in TA-TMA endothelial cell model. The expression of p-STAT3 and HIF-1α was significantly reduced when MK2206 was used. The expression of HIF-1α was significantly reduced when stattic was used. Rg1 reduced the toxicity of TA-TMA endothelial cells, as well as significantly reducing the expression of both HIF-1α and PAI-1. Furthermore, Rg1 also reduced the expression of AKT/STAT3/HIF-1α pathway. Conclusion: The expression of HIF-1α/PAI-1 was significantly increased in TA-TMA cellular and animal models. The AKT/STAT3/HIF-1α pathway was active in TA-TMA endothelial cells. Rg1 reduced the toxicity of TA-TMA endothelial cells, especially reducing the expression of HIF-1α and PAI-1.
- 2 November 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1764090
Open AccessGinsenoside Rg1 reduces endothelial cell injury in transplant-associated thromboticmicroangiopathy by regulating the expression of HIF-1α
Purpose: Transplant-Associated Thromboticmicroangiopathy (TA-TMA) is a common complication after hematopoietic stem cell transplantation (HSCT) with poor prognosis. This study aimed to explore the role and the regulation of Hypoxia-inducible factor-1α (HIF-1α) in TA-TMA. In addition, the effect of Ginsenoside Rg1 on TA-TMA endothelial cells was also explored. Method: We constructed a TA-TMA endothelial cell model using plasma from TA-TMA patients. A TA-TMA mouse model was successfully constructed by upregulating the expression of HIF-1α using Dimethyloxallyl Glycine(DMOG) in the HSCT mice. AKT inhibitor MK2206 and STAT3 inhibitor stattic were applied to TA-TMA endothelial cells, and the expression of AKT/STAT3/HIF-1α axis was detected. Endothelial cells were divided into control group, TA-TMA group and TA-TMA+Rg1 group. The proliferation, apoptosis and related proteins expression of endothelial cells were detected. Results: A-TMA plasma leaded to the toxicity of endothelial cells. The expression of p-AKT, p-STAT3, and HIF-1α/Plasminogen Activator Inhibitor-1 (PAI-1) was significantly increased in TA-TMA endothelial cell model. The expression of p-STAT3 and HIF-1α was significantly reduced when MK2206 was used. The expression of HIF-1α was significantly reduced when stattic was used. Rg1 reduced the toxicity of TA-TMA endothelial cells, as well as significantly reducing the expression of both HIF-1α and PAI-1. Furthermore, Rg1 also reduced the expression of AKT/STAT3/HIF-1α pathway. Conclusion: The expression of HIF-1α/PAI-1 was significantly increased in TA-TMA cellular and animal models. The AKT/STAT3/HIF-1α pathway was active in TA-TMA endothelial cells. Rg1 reduced the toxicity of TA-TMA endothelial cells, especially reducing the expression of HIF-1α and PAI-1.
- Open Access
- 1 September 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1900206
Lymphatic vascular aging and age-related bone loss: current status and future perspectives
Age-related bone loss is a major contributor to osteoporosis and fragility fractures in older adults. Skeletal aging is accompanied by reduced bone mineral density, impaired bone microarchitecture, chronic low-grade inflammation, and immune dysregulation. Lymphatic vascular aging refers to age-related structural and functional decline of lymphatic vessels. This decline impairs immune surveillance and inflammatory mediator clearance, thereby disrupting tissue homeostasis. Age-related lymphatic dysfunction impairs drainage and inflammatory clearance. This allows inflammatory mediators, including IL-6 and TNF-α, to persist in bone-associated tissues, thereby promoting osteoclastogenesis and resorption-dominant remodeling. Age-related lymphatic dysfunction also affects VEGF-C/VEGFR-3 signaling, chemokine-mediated immune trafficking, and marrow niche support. These changes link drainage failure to osteoimmune imbalance and delayed bone repair. Current evidence supports a link between lymphatic vascular dysfunction and skeletal degeneration. Most evidence comes from animal models, bone injury studies, or diseases with secondary lymphatic defects, whereas direct clinical evidence in human age-related osteoporosis remains limited. This review summarizes current evidence linking lymphatic dysfunction to skeletal degeneration, examines the context-dependent roles of lymphatic remodeling in skeletal homeostasis, and discusses emerging therapeutic strategies targeting the lymphatic-bone axis. Future studies should define clinically relevant lymphatic alterations and determine whether restoring lymphatic homeostasis can mitigate age-related bone loss.
- 1 September 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1900206
Open AccessLymphatic vascular aging and age-related bone loss: current status and future perspectives
Age-related bone loss is a major contributor to osteoporosis and fragility fractures in older adults. Skeletal aging is accompanied by reduced bone mineral density, impaired bone microarchitecture, chronic low-grade inflammation, and immune dysregulation. Lymphatic vascular aging refers to age-related structural and functional decline of lymphatic vessels. This decline impairs immune surveillance and inflammatory mediator clearance, thereby disrupting tissue homeostasis. Age-related lymphatic dysfunction impairs drainage and inflammatory clearance. This allows inflammatory mediators, including IL-6 and TNF-α, to persist in bone-associated tissues, thereby promoting osteoclastogenesis and resorption-dominant remodeling. Age-related lymphatic dysfunction also affects VEGF-C/VEGFR-3 signaling, chemokine-mediated immune trafficking, and marrow niche support. These changes link drainage failure to osteoimmune imbalance and delayed bone repair. Current evidence supports a link between lymphatic vascular dysfunction and skeletal degeneration. Most evidence comes from animal models, bone injury studies, or diseases with secondary lymphatic defects, whereas direct clinical evidence in human age-related osteoporosis remains limited. This review summarizes current evidence linking lymphatic dysfunction to skeletal degeneration, examines the context-dependent roles of lymphatic remodeling in skeletal homeostasis, and discusses emerging therapeutic strategies targeting the lymphatic-bone axis. Future studies should define clinically relevant lymphatic alterations and determine whether restoring lymphatic homeostasis can mitigate age-related bone loss.
- Open Access
- 23 April 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1827439
Mechanisms and treatments of lymphedema
Lymphedema refers to the interstitial edema caused by obstruction of lymph drainage. The clinical symptoms of lymphedema include local swelling and pain, thickened and rough skin, limited walking and repeated infection. Genetic mutation, fat deposition, aging and lymphatic filariasis may contribute to the pathogenesis of lymphedema. CD4 + T cells also promote the development of lymphedema. Cell junctions between adjacent lymphatic endothelial cells (LECs) are crucial to maintain the integrity of lymphatic vessels, and damage of these junctions increases the vessel permeability and induces lymphedema. VEGF-C-VEGFR3 signaling is a key regulator of lymphangiogenesis, whereas inflammatory mediators modulate lymphatic repair in a context-dependent manner. Current management includes conservative therapy and selected surgical approaches, while lymphangiogenic, pharmacologic, and cell-based treatments remain largely investigational. In this review, we summarize pathogenic factors associated with lymphedema, mechanisms regulating lymphatic endothelial permeability and lymphangiogenesis, and emerging therapeutic strategies.
- 23 April 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1827439
Open AccessMechanisms and treatments of lymphedema
Lymphedema refers to the interstitial edema caused by obstruction of lymph drainage. The clinical symptoms of lymphedema include local swelling and pain, thickened and rough skin, limited walking and repeated infection. Genetic mutation, fat deposition, aging and lymphatic filariasis may contribute to the pathogenesis of lymphedema. CD4 + T cells also promote the development of lymphedema. Cell junctions between adjacent lymphatic endothelial cells (LECs) are crucial to maintain the integrity of lymphatic vessels, and damage of these junctions increases the vessel permeability and induces lymphedema. VEGF-C-VEGFR3 signaling is a key regulator of lymphangiogenesis, whereas inflammatory mediators modulate lymphatic repair in a context-dependent manner. Current management includes conservative therapy and selected surgical approaches, while lymphangiogenic, pharmacologic, and cell-based treatments remain largely investigational. In this review, we summarize pathogenic factors associated with lymphedema, mechanisms regulating lymphatic endothelial permeability and lymphangiogenesis, and emerging therapeutic strategies.
- Open Access
- 22 December 2025
- Published by IMR Press in International Journal of Pharmacology
- Vol. 21 (8)
Vascular Dysfunction in Cardiac Cachexia: Molecular Mechanisms and Pharmacotherapies
Severe heart failure (HF) is accompanied by cardiac cachexia (CC), defined as significant weight loss, muscle atrophy, and metabolic abnormalities. Muscle wasting in patients with CC is closely associated with hormonal changes. Previous studies on the pathogenesis of CC have focused on the imbalance between catabolic and anabolic processes. Thus, this review focused on the role of endothelial dysfunction in CC. We summarized how inflammatory cytokines and neurohormonal factors cause vascular dysfunction, leading to reduced nutrient delivery and perfusion. Furthermore, we discuss both conventional and emerging therapeutic strategies that may ameliorate CC by targeting the vasculature. These include ghrelin, the vascular benefits of foundational HF drugs (angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor-neprilysin inhibitors (ARNIs), and beta-blockers), and the promise of novel agents, such as BTB and CNC homology 1 (BACH1) inhibitors and fibroblast growth factor 21 (FGF21) agonists. We also summarize the existing animal models of CC and discuss advanced imaging and omics technologies for future research. This review provides a novel perspective on CC pathogenesis and highlights promising avenues for therapeutic intervention.
- 22 December 2025
- Published by IMR Press in International Journal of Pharmacology
- Vol. 21 (8)
Open AccessVascular Dysfunction in Cardiac Cachexia: Molecular Mechanisms and Pharmacotherapies
Severe heart failure (HF) is accompanied by cardiac cachexia (CC), defined as significant weight loss, muscle atrophy, and metabolic abnormalities. Muscle wasting in patients with CC is closely associated with hormonal changes. Previous studies on the pathogenesis of CC have focused on the imbalance between catabolic and anabolic processes. Thus, this review focused on the role of endothelial dysfunction in CC. We summarized how inflammatory cytokines and neurohormonal factors cause vascular dysfunction, leading to reduced nutrient delivery and perfusion. Furthermore, we discuss both conventional and emerging therapeutic strategies that may ameliorate CC by targeting the vasculature. These include ghrelin, the vascular benefits of foundational HF drugs (angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor-neprilysin inhibitors (ARNIs), and beta-blockers), and the promise of novel agents, such as BTB and CNC homology 1 (BACH1) inhibitors and fibroblast growth factor 21 (FGF21) agonists. We also summarize the existing animal models of CC and discuss advanced imaging and omics technologies for future research. This review provides a novel perspective on CC pathogenesis and highlights promising avenues for therapeutic intervention.
- 8 December 2025
- Published by Springer Nature in Current Medical Science
- Vol. 45 (6) , 1428-1435
ARHGEF15 Promotes Endothelial Cell Migration Through the Regulation of STAT3 Signaling
Objective Rho guanine nucleotide exchange factor 15 (ARHGEF15) is a member of the RhoGEF family that activates the Rho protein. High ARHGEF15 expression is associated with poor prognosis in patients with pancreatic cancer. Although ARHGEF15 is abundantly expressed in endothelial cells, its detailed functions remain unknown. This study aimed to elucidate the effects of ARHGEF15 on endothelial cells and the underlying molecular mechanisms involved. Methods The ARHGEF15 gene was overexpressed or knocked down in human umbilical vein endothelial cells (HUVECs), and the results were validated via qRT-PCR and Western blotting. CCK8 and MTT assays were used to evaluate cell proliferation. Wound healing and transwell assays were used to assess cell migration. The activation of STAT3 signaling was examined by Western blotting, and STATTIC was used to inhibit STAT3 signaling. Results ARHGEF15 overexpression promoted the migration of HUVECs, and ARHGEF15 knockdown inhibited the migration of HUVECs. Neither the overexpression nor the knockdown of ARHGEF15 affected HUVEC proliferation. Furthermore, ARHGEF15 increased STAT3 phosphorylation in HUVECs. STATTIC treatment prevents ARHGEF15 overexpression-induced STAT3 phosphorylation and HUVEC migration. Conclusion ARHGEF15 increases HUVEC migration by regulating STAT3 signaling.
- 8 December 2025
- Published by Springer Nature in Current Medical Science
- Vol. 45 (6) , 1428-1435
ARHGEF15 Promotes Endothelial Cell Migration Through the Regulation of STAT3 Signaling
Objective Rho guanine nucleotide exchange factor 15 (ARHGEF15) is a member of the RhoGEF family that activates the Rho protein. High ARHGEF15 expression is associated with poor prognosis in patients with pancreatic cancer. Although ARHGEF15 is abundantly expressed in endothelial cells, its detailed functions remain unknown. This study aimed to elucidate the effects of ARHGEF15 on endothelial cells and the underlying molecular mechanisms involved. Methods The ARHGEF15 gene was overexpressed or knocked down in human umbilical vein endothelial cells (HUVECs), and the results were validated via qRT-PCR and Western blotting. CCK8 and MTT assays were used to evaluate cell proliferation. Wound healing and transwell assays were used to assess cell migration. The activation of STAT3 signaling was examined by Western blotting, and STATTIC was used to inhibit STAT3 signaling. Results ARHGEF15 overexpression promoted the migration of HUVECs, and ARHGEF15 knockdown inhibited the migration of HUVECs. Neither the overexpression nor the knockdown of ARHGEF15 affected HUVEC proliferation. Furthermore, ARHGEF15 increased STAT3 phosphorylation in HUVECs. STATTIC treatment prevents ARHGEF15 overexpression-induced STAT3 phosphorylation and HUVEC migration. Conclusion ARHGEF15 increases HUVEC migration by regulating STAT3 signaling.
- 29 August 2025
- Published by Wiley in FEBS Letters
- Vol. 599 (24) , 3606-3617
Circulating endothelial cells: the role in aging and brain pathology
Circulating endothelial cells (CECs) are mature vascular cells found in peripheral blood, originating from the vascular wall. Normally, they are present in low numbers in the body. CECs are released into the blood during tissue turnover or vascular injury from various factors. In diseased patients, blood often has a higher and variable CEC concentration. Changes in CEC count can serve as a biomarker, indicating conditions involving endothelial cell changes, including hematological diseases. They reflect disease progression, predict treatment response, and prognosis in disease therapy. CECs serve a purpose and are thought to contribute to endothelial damage, revealing changes in the prognosis of disease in elderly patients and those with brain disorders. Additionally, CECs act as biomarkers for tumor vascular damage and therapy monitoring in cancers like glioblastoma. To understand their role as disease markers in brain and elderly patients, it is important to study CECs under pathological conditions. This review details the relationship between CECs, aging, and brain disorders and provides insights for prevention and treatment.
- 29 August 2025
- Published by Wiley in FEBS Letters
- Vol. 599 (24) , 3606-3617
Circulating endothelial cells: the role in aging and brain pathology
Circulating endothelial cells (CECs) are mature vascular cells found in peripheral blood, originating from the vascular wall. Normally, they are present in low numbers in the body. CECs are released into the blood during tissue turnover or vascular injury from various factors. In diseased patients, blood often has a higher and variable CEC concentration. Changes in CEC count can serve as a biomarker, indicating conditions involving endothelial cell changes, including hematological diseases. They reflect disease progression, predict treatment response, and prognosis in disease therapy. CECs serve a purpose and are thought to contribute to endothelial damage, revealing changes in the prognosis of disease in elderly patients and those with brain disorders. Additionally, CECs act as biomarkers for tumor vascular damage and therapy monitoring in cancers like glioblastoma. To understand their role as disease markers in brain and elderly patients, it is important to study CECs under pathological conditions. This review details the relationship between CECs, aging, and brain disorders and provides insights for prevention and treatment.
- Top Cited Papers
- 23 May 2025
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 121, 35-46
Lymphatic Malformation: Classification, Pathogenesis, and Therapeutic Strategies
- 23 May 2025
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 121, 35-46
Top Cited PapersLymphatic Malformation: Classification, Pathogenesis, and Therapeutic Strategies
- Open Access
- 30 April 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1567293
Anti-endothelial cell antibodies in pathogenesis of vasculitis
Vasculitis is a group of syndromes characterized by inflammation, presence of autoantibodies and endothelial cells (ECs) damage, which lead to stenosis or occlusion of the vascular lumen. Anti-endothelial cell antibodies (AECAs) are a heterogeneous group of autoantibodies in vasculitis. AECAs bind to antigens and membrane-bound proteins of ECs, inducing inflammation, coagulation, and apoptosis. In this review, we discuss the pathological role of AECAs in different types of vasculitis. In addition, AECAs potentially induce alterations of ECs mechanical properties, and subsequently promotes angiogenic phenotypes in the occurrence of vasculitis.
- 30 April 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1567293
Open AccessAnti-endothelial cell antibodies in pathogenesis of vasculitis
Vasculitis is a group of syndromes characterized by inflammation, presence of autoantibodies and endothelial cells (ECs) damage, which lead to stenosis or occlusion of the vascular lumen. Anti-endothelial cell antibodies (AECAs) are a heterogeneous group of autoantibodies in vasculitis. AECAs bind to antigens and membrane-bound proteins of ECs, inducing inflammation, coagulation, and apoptosis. In this review, we discuss the pathological role of AECAs in different types of vasculitis. In addition, AECAs potentially induce alterations of ECs mechanical properties, and subsequently promotes angiogenic phenotypes in the occurrence of vasculitis.
- 12 January 2025
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 39 (1) , e70115
Cadmium Reduces VE‐Cadherin Expression in Endothelial Cells Through Activation of the Notch Signaling Pathway
Cadmium (Cd) is a toxic heavy metal which induces vascular disorders. Previous studies suggest that Cd in the bloodstream affects vascular endothelial cells (ECs), potentially contributing to vascular‐related diseases. However, the molecular mechanisms of effects of Cd on ECs remain poorly understood. Notch signaling pathway abnormalities have been implicated in ECs disruption. The present study aims to investigate the effect of low Cd concentrations on the Notch signaling pathway in ECs. Mice were treated with low concentration of Cd (2.28 mg/kg), and tissues were collected for examination of mRNA and protein levels of Notch pathway components and VE‐cadherin, a major junctional protein in ECs. We found that Cd treatment increases expression of NICD1, Hes1, Hey1, Hey2 and decreases expression of VE‐cadherin in brain and kidney tissues. In vitro, a low concentration of Cd (1 μM) also induces increase expression of NICD1, Hes1, Hey1, Hey2, and decrease expression of VE‐cadherin in human umbilical vein endothelial cells (HUVECs). Low concentration of Cd increased the permeability of HUVECs. We also found that Notch signaling negatively regulates the expression of VE‐cadherin. In addition, DAPT, a Notch pathway inhibitor, prevents Cd‐induced reduction in VE‐cadherin expression in HUVECs. In summary, these findings revealed that Cd exposure decreases VE‐cadherin expression through activation of the Notch signaling pathway.
- 12 January 2025
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 39 (1) , e70115
Cadmium Reduces VE‐Cadherin Expression in Endothelial Cells Through Activation of the Notch Signaling Pathway
Cadmium (Cd) is a toxic heavy metal which induces vascular disorders. Previous studies suggest that Cd in the bloodstream affects vascular endothelial cells (ECs), potentially contributing to vascular‐related diseases. However, the molecular mechanisms of effects of Cd on ECs remain poorly understood. Notch signaling pathway abnormalities have been implicated in ECs disruption. The present study aims to investigate the effect of low Cd concentrations on the Notch signaling pathway in ECs. Mice were treated with low concentration of Cd (2.28 mg/kg), and tissues were collected for examination of mRNA and protein levels of Notch pathway components and VE‐cadherin, a major junctional protein in ECs. We found that Cd treatment increases expression of NICD1, Hes1, Hey1, Hey2 and decreases expression of VE‐cadherin in brain and kidney tissues. In vitro, a low concentration of Cd (1 μM) also induces increase expression of NICD1, Hes1, Hey1, Hey2, and decrease expression of VE‐cadherin in human umbilical vein endothelial cells (HUVECs). Low concentration of Cd increased the permeability of HUVECs. We also found that Notch signaling negatively regulates the expression of VE‐cadherin. In addition, DAPT, a Notch pathway inhibitor, prevents Cd‐induced reduction in VE‐cadherin expression in HUVECs. In summary, these findings revealed that Cd exposure decreases VE‐cadherin expression through activation of the Notch signaling pathway.